Bharat Book

Biosimilar Development Capabilities of Indian Players: Partnerships & Acquisitions

Press Release   •   Aug 09, 2012 15:23 IST

India Biosimilar Market Analysis
 
 As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars. They are increasingly partnering with large multinational corporations for clinical trials, regulatory approval processes in the EU/US, and marketing to physicians as well as consumers. http://www.bharatbook.com/healthcare-market-research-reports/india-biosimilar-market-analysis.html
 
 Launching biosimilar products in India also provides firms with an advantage to develop their post-marketing safety and efficacy data. This is specifically significant for biosimilar products as even minor changes in manufacturing processes may lead to serious health issues. One of the key challenges regarding biosimilar products is immunogenicity. Studies that compare innovator biologics and biosimilars often report differences in aggregate levels, protein concentration, stability, conformational states, and impurity profiles. Nevertheless, the biosimilar market is still nascent to gauge which of these differences is significant in determining the safety and efficacy impacts.
 
 The Indian biosimilar market includes product segments such as insulin, erythropoietin, GCSF, hormones, interferon alpha, thrombolytics, plasma proteins, vaccines, and others. Of these, insulin is the largest segment of the biosimilar market followed by erythropoietin and GCSF. In 2011, there were about 15 epoetin, 8 G-CSF and 4 insulin biosimilars available in the Indian market. The acceptability of biosimilars is higher in the domestic market. Biosimilar substitution is automatic and can take place as soon as a biosimilar is launched.
 
 “India Biosimilar Market Analysis” research gives detailed insight on various aspects related the biosimilar market in India like Market Overview, Biosimilar Pipeline Analysis, Biosimilar Development Capabilities of Indian Players, detailed insight into recently announce Guidelines for the Development & Marketing of Biosimilar and competitive landscape.
 
 1. India Biosimilar Market Overview
 2. Indian Market for Biosimilar by Drug Class
 3. Biosimilar Pipeline Analysis
 4. Biosimilar Development Capabilities of Indian Players: Partnerships & Acquisitions
 5. Factors Driving the Market
 6. Guidelines for Development & Marketing of Biosimilar
 7. Indian Biosimilar Market Future Outlook
 8. Indian Biosimilar Drugs to Enter the US & European Market
 9. Competitive Landscape
 
 For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/india-biosimilar-market-analysis.html                    
 
 Or
 
 Contact us at :
 
 Bharat Book Bureau
 Ph.: + 91 22 27810772 / 27810773
 Fax: + 91 22 27812290
 Email: info@bharatbook.com
 Website: www.bharatbook.com
 Follow us on twitter: http://twitter.com/#!/Sandhya3B
 Our Blogs : http://bharatbookblog.wordpress.com/
 

Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.